Equities Analysts Set Expectations for SGMO FY2024 Earnings

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - HC Wainwright decreased their FY2024 earnings per share estimates for Sangamo Therapeutics in a report released on Tuesday, November 5th. HC Wainwright analyst P. Trucchio now anticipates that the biopharmaceutical company will post earnings per share of ($0.40) for the year, down from their prior estimate of ($0.23). HC Wainwright currently has a "Buy" rating and a $10.00 target price on the stock. The consensus estimate for Sangamo Therapeutics' current full-year earnings is ($0.47) per share. HC Wainwright also issued estimates for Sangamo Therapeutics' Q4 2024 earnings at $0.07 EPS, Q1 2025 earnings at ($0.05) EPS, Q2 2025 earnings at ($0.04) EPS, Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at $0.07 EPS, FY2025 earnings at ($0.06) EPS, FY2026 earnings at $0.10 EPS, FY2027 earnings at $0.29 EPS and FY2028 earnings at $0.63 EPS.

Separately, StockNews.com initiated coverage on Sangamo Therapeutics in a research note on Sunday, July 28th. They issued a "sell" rating for the company.

Sangamo Therapeutics Stock Performance

Shares of SGMO stock traded up $0.34 during trading hours on Thursday, reaching $2.81. The company had a trading volume of 15,355,811 shares, compared to its average volume of 6,843,436. Sangamo Therapeutics has a twelve month low of $0.29 and a twelve month high of $2.97. The company has a market capitalization of $585.10 million, a P/E ratio of -1.99 and a beta of 1.10. The stock's fifty day simple moving average is $1.08 and its 200 day simple moving average is $0.77.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last posted its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.01). Sangamo Therapeutics had a negative net margin of 2,033.69% and a negative return on equity of 273.25%. The company had revenue of $0.36 million during the quarter, compared to analyst estimates of $11.40 million.

Institutional Investors Weigh In On Sangamo Therapeutics

A number of hedge funds have recently bought and sold shares of the business. Acadian Asset Management LLC grew its stake in Sangamo Therapeutics by 4.0% during the 1st quarter. Acadian Asset Management LLC now owns 4,943,260 shares of the biopharmaceutical company's stock valued at $3,311,000 after purchasing an additional 192,385 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in Sangamo Therapeutics by 58.8% during the 2nd quarter. Renaissance Technologies LLC now owns 4,126,577 shares of the biopharmaceutical company's stock worth $1,479,000 after buying an additional 1,528,600 shares during the last quarter. Marshall Wace LLP lifted its holdings in Sangamo Therapeutics by 56.3% during the 2nd quarter. Marshall Wace LLP now owns 576,219 shares of the biopharmaceutical company's stock worth $207,000 after buying an additional 207,476 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in Sangamo Therapeutics during the 1st quarter worth approximately $331,000. Finally, Vontobel Holding Ltd. lifted its holdings in Sangamo Therapeutics by 412.3% during the 3rd quarter. Vontobel Holding Ltd. now owns 300,000 shares of the biopharmaceutical company's stock worth $259,000 after buying an additional 241,440 shares during the last quarter. Institutional investors and hedge funds own 56.93% of the company's stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.